Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 3/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722757 | 1.00 | MME (0.62) | MMEECE1PPARAPPARGALDH1A1 | |
| SCHEMBL3569541 | 1.00 | MME (0.62) | MMEECE1PPARAPPARGALDH1A1 | |
| SCHEMBL11124167 | 0.95 | MME (0.64) | MMEECE1PPARAPPARGALDH1A1 | |
| Phenylacetic Acid SCHEMBL1579412 | 0.93 | CASP1 (0.58) | MMEECE1PPARAPPARGALDH1A1 | |
| SCHEMBL8955765 | 0.91 | CTSL (0.57) | MMEECE1ALDH1A1PSMB1CASP1 | |
| SCHEMBL7688519 | 0.91 | PSMB1 (0.57) | MMEECE1PSMB1CASP1CTSK | |
| SCHEMBL11121980 | 0.91 | MME (0.60) | MMEECE1PSMB1CASP1 | |
| SCHEMBL8078067 | 0.90 | PSMB1 (0.56) | MMEECE1PSMB1CASP1CTSK | |
| SCHEMBL20495590 | 0.89 | MME (0.61) | MMEECE1PPARAPPARGPSMB1 | |
| SCHEMBL20495591 | 0.89 | MME (0.61) | MMEECE1PPARAPPARGPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114682232-B | Preparation method and application of bridged cyclodextrin/chitosan difunctional chiral monolithic column | 福州大学 | 2023-04-21 | — | — | CN | claimed |
| CN-114682232-A | Preparation method and application of bridged cyclodextrin/chitosan bifunctional chiral monolithic column | 福州大学 | 2022-07-01 | — | — | CN | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-1093701-A | Antiretroviral hydrazine derivative | CIBA GEIGY AG (CH) | 1994-10-19 | — | — | CN | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-H642-H | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1989-06-06 | — | — | US | disclosed |
| US-4711952-A | IMMUNOSTIMULATIVE, OR IMMUNOSUPPRESSORY AGENTS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOUVYROBU (CS) | 1987-12-08 | — | — | US | disclosed |
| EP-0232435-A2 | Serum thymic factor peptide analogs and a process for the preparation thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1987-08-19 | — | — | EP | disclosed |
| US-4237272-A | BACTERICIDES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | MME 2475/4885ECE1 1982/4885PPARA 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.